New pill shows promise against tough lung cancer mutations in phase 3 trial

NCT ID NCT06956001

Recruiting now Disease control Sponsor: Allist Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Feb 16, 2026 · Last updated Apr 28, 2026 · Updated 9 times

Summary

This study tests a new daily pill, firmonertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has specific EGFR mutations (PACC or L861Q). About 300 participants will be randomly assigned to receive either the pill or chemo. The goal is to see if the pill can delay cancer growth and improve quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ethics Committee of cancer hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Shandong Tumor Hospital
RECRUITING

Shandong, Jinan, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EGFR EGFR NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)